Morgan Stanley’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-124,736
| Closed | -$499K | – | 8260 |
|
|
2025
Q2 | $499K | Sell |
124,736
-11,732
| -9% | -$29.1K | ﹤0.01% | 5458 |
|
|
2025
Q1 | $124K | Sell |
136,468
-11,006
| -7% | -$15.3K | ﹤0.01% | 5918 |
|
|
2024
Q4 | $409K | Sell |
147,474
-11,372
| -7% | -$43.3K | ﹤0.01% | 5505 |
|
|
2024
Q3 | $831K | Buy |
158,846
+79,948
| +101% | +$415K | ﹤0.01% | 5147 |
|
|
2024
Q2 | $352K | Sell |
78,898
-45,348
| -36% | -$220K | ﹤0.01% | 5446 |
|
|
2024
Q1 | $952K | Sell |
124,246
-106,714
| -46% | -$585K | ﹤0.01% | 4972 |
|
|
2023
Q4 | $984K | Buy |
230,960
+204,588
| +776% | +$727K | ﹤0.01% | 5305 |
|
|
2023
Q3 | $111K | Sell |
26,372
-7,213
| -21% | -$36.7K | ﹤0.01% | 5851 |
|
|
2023
Q2 | $187K | Buy |
33,585
+14,229
| +74% | +$84.1K | ﹤0.01% | 5676 |
|
|
2023
Q1 | $111K | Buy |
19,356
+6,210
| +47% | +$16.4K | ﹤0.01% | 5964 |
|
|
2022
Q4 | $13.8K | Sell |
13,146
-9,138
| -41% | -$16K | ﹤0.01% | 6822 |
|
|
2022
Q3 | $59K | Sell |
22,284
-18,890
| -46% | -$68.3K | ﹤0.01% | 6334 |
|
|
2022
Q2 | $197K | Buy |
41,174
+25,237
| +158% | +$110K | ﹤0.01% | 5908 |
|
|
2022
Q1 | $64K | Sell |
15,937
-3,503
| -18% | -$20.6K | ﹤0.01% | 6576 |
|
|
2021
Q4 | $133K | Buy |
19,440
+1,446
| +8% | +$12.5K | ﹤0.01% | 6277 |
|
|
2021
Q3 | $209K | Sell |
17,994
-24,760
| -58% | -$386K | ﹤0.01% | 5973 |
|
|
2021
Q2 | $728K | Buy |
42,754
+18,204
| +74% | +$317K | ﹤0.01% | 5273 |
|
|
2021
Q1 | $486K | Buy |
24,550
+4,897
| +25% | +$108K | ﹤0.01% | 5170 |
|
|
2020
Q4 | $405K | Buy |
19,653
+18,402
| +1,471% | +$438K | ﹤0.01% | 5215 |
|
|
2020
Q3 | $33K | Buy |
+1,251
| New | +$31.1K | ﹤0.01% | 5864 |
|
Morgan Stanley's INZY Position: Q3 2025 in Review
Morgan Stanley sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 124,736 shares — an estimated $499K sold.
Morgan Stanley first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $984K in Q4 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Morgan Stanley reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 124,736 Inozyme Pharma shares in Q3 2025, an estimated $499K.
- Morgan Stanley first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- Morgan Stanley's Inozyme Pharma position peaked at $984K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.